This ex-penny stock’s tipped for a 175-235% surge by City analysts!

Select analysts reckon this 28p former penny stock has the potential to double or even treble investors’ money in the years ahead.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I continue to see potentially lucrative opportunities in the penny stock and small-cap space. Most of these shares have been hammered since interest rates surged higher in 2022.

That’s understandable because higher rates increase borrowing costs and raise the risk of smaller enterprises going under. However, I think there’s been an overreaction in some cases.

One is Creo Medical (LSE: CREO). Despite trading at 28.5p, I call it a former penny stock as its £103m market-cap just edges above the £100m threshold typically used to classify such shares.

According to broker Deutsche Bank, it has the potential to surge 171% to 80p. Meanwhile, Cavendish Capital Markets analyst Chris Donnellan has a 99p price objective for the stock.

Of course, there’s no guarantee it will ever reach 99p (or even 30p). But if it does, that’s a whopping 235% above the current price!

Innovative devices

Creo’s a medical technology company specialising in electrosurgical devices. These treat pre-cancer and cancer patients with greater accuracy, minimising damage to surrounding tissue during endoscopic (minimally invasive) surgery.

The firm’s innovative flagship product, Speedboat, can inject, dissect, and coagulate (promote clotting) through a single instrument. This is powered by a technology platform called Croma, which integrates advanced microwave and radiofrequency energy sources.

This can turn what would typically be a diagnostic endoscopy into a minimally invasive procedure, creating better outcomes for patients and saving healthcare systems a small fortune.

For example, recent NHS Supply Chain data confirmed net cash savings of £687k from 130 Speedboat procedures at one NHS Trust. That’s just over £5,000 saved per procedure.

A high-growth business

Last year, the firm reported revenue of £30.8m. Brokers see that increasing by 29% this year to reach around £40m before topping £53m in 2025 (32% year-on-year growth). So revenue’s expected to accelerate which, as a shareholder, I’m hoping will be a positive for the stock.

However, the company’s yet to turn a profit. It recorded a £21.7m net loss last year. This lack of profitability’s a key risk with the stock and largely explains its decline.

Again though, progress is being made here. The firm expects to achieve cashflow break even in 2025, while forecasts see the pre-tax loss shrinking to around £4m by then. It ended last year with a net cash position of £18.5m.

More growth seems likely

Interestingly, the share price was above 200p as recently as August 2021 when the firm was posting only £9.4m in revenue. Now that figure’s forecast to surge above £53m and the share price is down at 28p.

It wouldn’t surprise me to see the stock rise above 100p again if the firm keeps growing and, crucially, moves closer to profitability.

More growth seems likely to me. Its latest Speedboat UltraSlim device, which improves compatibility with a broader range of endoscopes, is already being used in the EU, US, Latin America and Asia Pacific.

Meanwhile, its training programme continues to grow worldwide users, with a 119% increase over the course of 2023. The more surgeons trained, the more procedures are likely to occur, increasing Creo’s revenue from the single-use instruments that need to be replaced after each procedure.

I added to my holding in July. Now I’m crossing my fingers for those 100%-200% share price gains!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Creo Medical. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »